#FastMoney и #Turbo в компании #Tirus / #Тайрус | брифинг

CNBC Television Homebuilders report: Nailing down the new homes trade

CNBC Television Microsoft plans to become carbon negative by 2030

CNBC Television Significant amount of bankruptcies possible in high-yield sector in 2021: Portfolio manager

CNBC Television Hedging is key strategy for investors in second half, says Citi Global Wealth's head of investments

CNBC Television Cornerstone Macro's Carter Worth charts where banks could be headed

CNBC Television Retail investors are here to stay: Betterment's Dan Egan

CNBC Television Final Trade: Amazon, Delta Air Lines and Snap

CNBC Television Strategas' Chris Verrone lays out 3 stock picks for the new year

CNBC Television Lucid, Ford and GM make waves in electric vehicle space

CNBC Television Have a little more pain left in October: Stock Trader's Almanac's Hirsch

CNBC Television Would you rather: Snap vs. Twitter: 3 trades

CNBC Television Foxconn invests in Lordstown Motors, company will deliver first all-electric truck next year

CNBC Television Loup's Gene Munster: Once again, Apple proves critics wrong

CNBC Television Alphabet is next week's 'most controversial' tech earning next week, says Jefferies Brent Thill

CNBC Television Stocks are getting smoked as Wall Street can't shake trade fears

CNBC Television This number on the 10-year yield could wreck the market's hottest trade

CNBC Television Samsung betting you'll flip out over new foldable phones

CNBC Television Why the chartmaster is switching from the insurers to the big banks

CNBC Television It's do or die for Amazon this Prime Day, says former Walmart U.S. CEO

CNBC Television Traders talk MAGA stocks and the state of the tech sector

CNBC Television Microsoft to excel Jefferies Brent Thill says yes and here's why

CNBC Television Wells Fargo's Fed prediction: Stocks should rally and yields fall on decision day

CNBC Television As markets rally, technician says the charts suggest more gains ahead

CNBC Television John Crowley, Amicus Therapeutics discusses drug trial results for Pompe disease